Holen Sie sich die Stockscreener-App
36.27
4.28%
1.49
Handel nachbörslich:
36.25
-0.02
-0.06%
Schlusskurs vom Vortag:
$34.78
Offen:
$35.22
24-Stunden-Volumen:
3.43M
Relative Volume:
1.07
Marktkapitalisierung:
$5.57B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-284.08M
KGV:
-14.97
EPS:
-2.4234
Netto-Cashflow:
$-234.65M
1W Leistung:
+2.11%
1M Leistung:
-6.45%
6M Leistung:
+287.91%
1J Leistung:
+339.64%
1-Tages-Spanne:
$34.50
$37.00
1-Wochen-Bereich:
$32.93
$37.00
52-Wochen-Spanne:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Vergleichen Sie COGT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.27 | 5.34B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-10 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-10-16 | Eingeleitet | Stifel | Hold |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Cogent Biosciences announces presentation at the 44th annual J.P. Morgan Healthcare conference - MarketScreener
Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COGT Stock News - GuruFocus
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences down after market close on insider sales - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat
Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st
EV Market: Will Cogent Biosciences Inc stock see PE expansionJuly 2025 News Drivers & Capital Efficiency Focused Ideas - moha.gov.vn
Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barron's
Cogent Biosciences Stock Jumps in 2025 as Executives Sell Shares - Barron's
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest - DirectorsTalk Interviews
When Will Cogent Biosciences, Inc. (NASDAQ:COGT) Become Profitable? - 富途牛牛
Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing - ts2.tech
Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat
Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis
Wave of High-Level Insider Sales Rocks Cogent Biosciences - TipRanks
Cogent Biosciences presents full SUMMIT results of bezuclastinib - MSN
Cogent Biosciences (COGT) Shares Drop Following Insider Sales - GuruFocus
Cogent Biosciences stock falls after multiple insider sales By Investing.com - Investing.com UK
Cogent Biosciences stock falls after multiple insider sales - Investing.com
Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat
Insider Sell: Jessica Sachs Sells 82,642 Shares of Cogent Biosci - GuruFocus
Cogent Biosciences Insider Sold Shares Worth $3,486,600, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $3,198,245, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $2,978,360, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $2,515,500, According to a Recent SEC Filing - MarketScreener
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis - The Globe and Mail
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - ts2.tech
Cogent Biosciences Submits New Drug Application for Bezuclastinib for Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Insider Monkey
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis - MSN
Certain Stock Options of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2025. - MarketScreener
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Squarepoint Ops LLC Purchases Shares of 101,518 Cogent Biosciences, Inc. $COGT - MarketBeat
What analysts say about Cogent Biosciences Inc stockMarket Sentiment Surveys & Avoid Market Traps With Pro-Level Warnings - earlytimes.in
Cogent Biosciences Earnings Notes - Trefis
Cogent Biosciences Inc (COGT) Bonds - GuruFocus
Assenagon Asset Management S.A. Purchases 380,345 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
What hedge fund activity signals for Cogent Biosciences Inc. stockJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
Why Cogent Biosciences Inc. stock is rated strong buyJuly 2025 Retail & Fast Gain Stock Trading Tips - ulpravda.ru
Will Cogent Biosciences Inc. stock outperform Nasdaq indexJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Wall Street Zen Upgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat
Officer Pinnow Acquires 119,200 Of Cogent Biosciences Inc [COGT] - TradingView — Track All Markets
How Cogent Biosciences Inc. stock performs in stagflation2025 Market Sentiment & Smart Allocation Stock Tips - Улправда
Cogent Biosciences (COGT): JP Morgan Raises Price Target to $67 - GuruFocus
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):